People living with CTEPH face significant symptoms that affect daily life, even when receiving treatment, a real-world U.S.
Early diagnosis of pulmonary arterial hypertension improves five-year survival by 42%, compared with delayed diagnosis, a ...
Instead of resolutions, columnist Jen Cueva suggests a strategy that better reflects the reality of living with a rare disease like PH.
Researchers in China report that a simple heart ultrasound measure of left ventricular underfilling is a valuable prognostic ...
A study found that pulmonary hypertension often resolves within a year in premature infants with BPD, though many still ...
Researchers have pinpointed Jagged-2, a signaling protein, as a potential therapeutic target for slowing or halting the progression of pulmonary arterial hypertension (PAH), based on a rat study.
Two Phase 3 clinical trials are now recruiting participants to test Tenax Therapeutics‘ experimental therapy TNX-103 (oral levosimendan) in people with pulmonary hypertension associated with heart ...
Uptravi (selexipag) may reduce blood pressure in the lungs of children with pulmonary arterial hypertension (PAH) and help them perform physical tasks, according to a meta-analysis. However, more long ...
A committee of the European Medicines Agency (EMA) has recommended expanding the indication for Winrevair (sotatercept-csrk), Merck’s approved injection therapy for adults with pulmonary arterial ...
Tiakis Biotech is set to advance its experimental therapy tiprelestat into a Phase 2 clinical trial for pulmonary arterial hypertension (PAH), after successfully finalizing the data package required ...
When you live with a chronic and complex illness, complications and side effects from the medications to treat it are always lurking around the corner — even in the most stable of times. The more ...
Pulmonary hypertension (PH) is a rare but life-threatening disease that affects the pulmonary arteries, making them narrow and thick. The vessels, which are responsible for transporting blood from the ...